Instead, work with both your current provider and your new Wegovy prescriber to coordinate the transition, which typically involves finishing your current compounded supply while beginning the Wegovy prescription at an appropriate dose level
Pink to light red for B12 formulations

Here's what could derail the thesis: Regulatory & Pricing Pressure Government price controls on GLP-1 drugs (Trump administration deal includes price cuts) Medicare/Medicaid coverage expansion requires discounting International pricing pressures as volumes increase Competition Intensifying Novo Nordisk fighting back with oral GLP-1 programs Amgen, Pfizer, and others entering the space Compounding pharmacies eating market share during supply shortages Operational Challenges Manufacturing constraints still limiting supply in some markets CVS formulary changes disrupted Zepbound access temporarily Volume growth partially offset by 10% lower realized prices in Q3 Valuation Risk At ~$930B market cap, expectations are sky-high Any guidance miss or pipeline disappointment will be punished severely Forward P/E of ~42 leaves little room for error Pipeline Execution Orforglipron approval timing uncertain Alzheimer's market adoption slower than hoped Clinical trial failures in crowded pipeline Smart investors acknowledge risks while staying focused on the long-term thesis

Clinical trials of VNS in obesity related diseases Multiple neuromodulation clinical trials for obesity and obesity related conditions have been conducted (Table 1)
Schedule changes : Patients may permanently change their injection day if needed for travel, work schedules, or other commitments
2,7,9,28-31 Step 1Stop Inciting Agent, if Applicable: In the case of EDKA induced by SGLT2i or drug intoxication, the inciting agent(s) must be discontinued as soon as EDKA is diagnosed